Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III equivalence trial of TX05 versus Herceptin in HER2-positive early breast cancer
2017-004190-13Phase 3Completed
- Sponsor
- Tanvex BioPharma
- Start
- Feb 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing TX05 arm with Herceptin arm (2 arms). Primary endpoint: Pathologic complete response. Started Feb 2018; status: completed.
02
Drugs
TrastuReltrastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2017-004190-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004190-13.